Effect of Renal Impairment on the Pharmacokinetics of NN9535

Part of paid clinical trials in Miami, Florida.

Sponsor
Novo Nordisk A/S
Study ID
NCT00833716
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    10 mg/mL of semaglutide solution for s.c. injection, single dose

Study Details

This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.

Key Dates

Start date
Feb 2, 2009
Status verified
Mar 2017
Primary completion
Jul 26, 2010
Completion
Jul 26, 2010

Study Design

Enrollment
62 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A

Primary Outcome Measure

AUC of NN9535 [ Time Frame: at 21 days ]

Locations (3)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SiteMiamiFlorida33014-
Novo Nordisk Investigational SiteOrlandoFlorida32806-
Novo Nordisk Investigational SiteKnoxvilleTennessee37920-

Find similar trials in Miami, FL

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Miami, FLNovo Nordisk Investigational Site· Orlando, FLNovo Nordisk Investigational Site· Knoxville, TN

Related Studies